Huron Consulting Group Inc. (NASDAQ: HURN), a leading provider of
business consulting services, today announced that it intends to offer,
subject to market conditions and other factors, $225 million aggregate
principal amount of convertible senior notes due 2019 (the "Convertible
Notes") in a private offering to qualified institutional buyers pursuant
to Rule 144A under the Securities Act of 1933, as amended (the
"Securities Act"). The Company expects to grant an option to the initial
purchasers to purchase, within a period of 13 days beginning on, and
including, the date the Convertible Notes are first issued, up to an
additional $25 million aggregate principal amount of Convertible Notes.
Hotels Corporation (NYSE: H) announced today that a Hyatt affiliate
has entered into a management services agreement with 5 Star
Empreendimentos Imobiliários Ltda for a Park Hyatt hotel in Foz do
Iao Kun Group Holding Company Limited (“IKGH”) (NASDAQ:IKGH), which
operates through its subsidiaries and related promotion entities that
act as VIP room gaming promoters and collaborator, today announced
unaudited Rolling Chip Turnover (as defined below) for the month of
August 2014 at the company’s VIP rooms in Macau was US$1.53 billion, up
3% year-over-year, compared to US$1.49 billion for the month of August
IndexIQ, a leading developer of index-based alternative investment
solutions, today announced the mergers and acquisitions (M&A) deals to
which investors can gain exposure in the IQ Merger Arbitrage ETF
(Ticker: MNA) .
- Infinity to Receive $275 Million Upfront Payment and $530 Million in Potential Milestones - - Companies to Jointly Develop and Commercialize Duvelisib in U.S., with Equal Profit Share; Infinity to Receive Royalties on Sales Outside the U.S. -
- Infinity to Host Conference Call Today at 8:30 A.M. ET/7:30 A.M. CT - CAMBRIDGE, Mass.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) and AbbVie Inc. (NYSE:
ABBV) today announced that they have entered into a global collaboration
to develop and commercialize duvelisib (IPI-145), Infinity’s oral
inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, for
the treatment of patients with cancer.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that it
has entered into a master clinical supply agreement with Roche under
which Roche will supply Gazyva TM (obinutuzumab) to Infinity
for use in planned clinical studies to evaluate the combination of
Gazyva and duvelisib (IPI-145), Infinity’s oral inhibitor of
phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with
hematologic malignancies, or blood cancers.
Shares of Infinity Pharmaceuticals (INFI) soared 46% in premarket trade Wednesday, after the company said it would receive an upfront payment of $275 million from AbbVie (ABBV) as part of a new collaboration to develop and commercialize Infinity's duvelisib, a treatment for blood cancers.
Ingersoll Rand (NYSE:IR), a world leader in creating comfortable,
sustainable and efficient environments, has been ranked 27 th
by Workforce Magazine on its inaugural list of 100 top-performing
human resources (HR) organizations.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.